Tesamorelin dose guide

Tesamorelin dosage

The only GHRH analog currently FDA-approved (to reduce excess abdominal fat in HIV lipodystrophy). Tesamorelin targets visceral fat, the deep abdominal fat around the organs: in two phase 3 trials it cut visceral fat about 15% in 26 weeks. Commonly reported: waist and belly shrinking while body weight barely moves, with injection-site redness and early joint aches.

Dose range

1–2 mg (research range). Studied in research — not a recommendation. FDA-approved as Egrifta WR (1.28 mg) and Egrifta SV (1.4 mg), SubQ once daily, to reduce excess abdominal fat in adults with HIV lipodystrophy.

How often

Daily

A typical run

FDA approval context: daily use. Community typically runs 12–24 weeks. Reassess at 3 months.

How it’s taken

Vial: SubQ injection

Evidence

Established: Clinical trials or FDA-approved use exists

Half-life

~8–11 min (current EGRIFTA SV/WR labels; the original label listed ~26 min)

Tesamorelin on your syringe

With a 10 mg vial and 2 mL of water (5 mg in every mL), on a 0.5 mL (50-unit) U-100 insulin syringe: the low end, 1 mg, is 20 units; and the high end, 2 mg, is 40 units. 10 doses in the vial at the low end. All U-100: 100 units to the mL. A U-40 syringe reads differently.

What to take alongside each peptideTesamorelin in the peptide libraryThe Dose Guide: every peptide

More growth hormone peptides

• Ipamorelin 200–300 mcg
• CJC-1295 with DAC 1–2 mg
• CJC-1295 no DAC 100–200 mcg
• Sermorelin 200–500 mcg
• GHRP-2 100–300 mcg
• GHRP-6 100–300 mcg
• Hexarelin 100–200 mcg
• MK-677 10–25 mg
• Fragment 176-191 250–500 mcg
• IGF-1 LR3 20–50 mcg
• PEG-MGF 200–400 mcg
• Follistatin-344 100–200 mcg
• HGH 1–4 IU

A community reference, not medical advice. Each range is what has been studied or is commonly run, never a dose for you.